Opus GeneticsIRD +7.38%24 9-Day RSI is 48.55 as of Jun. 28, 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,423 Biotechnology companies, Opus Genetics ranks worse than 55.09% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-06-28), Opus Genetics's 9-Day RSI is 48.55.
The industry rank for Opus Genetics's 9-Day RSI or its related term are showing as below:
IRD's 9-Day RSI is ranked worse than 55.09% of 1423
companies
in the Biotechnology industry
Industry Median: 45.82
vs IRD: 48.55
Opus Genetics (NAS:IRD) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Opus Genetics 9-Day RSI Related Terms
IRD vs IFRX, RGNX, LRMR: 9-Day RSI Comparison
For the Biotechnology subindustry, Opus Genetics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Opus Genetics's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (IRD) has a 9-Day RSI of 48.55 as of Jun. 28, 2026. According to the industry distribution chart, Opus Genetics ranks #784 out of 1423 companies in the Biotechnology industry, placing it in the top 55.1%.
Is Opus Genetics' 9-Day RSI too high?
Opus Genetics' current 9-Day RSI is 48.55. The Biotechnology industry median 9-Day RSI is 45.82. Opus Genetics' value of 48.55 is 6% above this industry median. Based on the distribution chart, Opus Genetics ranks #784 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' 9-Day RSI compare to IFRX and RGNX?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #784 out of 1423 companies for 9-Day RSI. This places Opus Genetics in the lower half of its industry. The industry median 9-Day RSI is 45.82. Opus Genetics' value of 48.55 is 6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 45.82, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Opus Genetics's current 9-Day RSI of 48.55 is 6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 45.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Opus Genetics's current 9-Day RSI is 48.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $4.00 — trading 981.1% above its estimated fair value. The current 9-Day RSI is 48.55 and 6% above the Biotechnology industry median of 45.82. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Opus Genetics (IRD), the current 9-Day RSI is 48.55 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $4.00 is trading 981.1% above its estimated GF Value™ of $0.37.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
9-Day RSI: 48.55
GF Value™: $0.37 vs. price of $4.00 (981.1% above fair value)
Industry Position: 6% above the Biotechnology median (#784 of 1423)
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score
Get the complete analysis for IRD
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 